Cargando…

GD2 expression in breast cancer

Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-low and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orsi, Giulia, Barbolini, Monica, Ficarra, Guido, Tazzioli, Giovanni, Manni, Paola, Petrachi, Tiziana, Mastrolia, Ilenia, Orvieto, Enrico, Spano, Carlotta, Prapa, Malvina, Kaleci, Shaniko, D’Amico, Roberto, Guarneri, Valentina, Dieci, Maria Vittoria, Cascinu, Stefano, Conte, Pierfranco, Piacentini, Federico, Dominici, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458232/ https://www.ncbi.nlm.nih.gov/pubmed/28415563 http://dx.doi.org/10.18632/oncotarget.16363

Ejemplares similares

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
por: Prapa, Malvina, et al.
Publicado: (2015)

Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
por: Spano, Carlotta, et al.
Publicado: (2019)

Anti-GD2 CAR MSCs against metastatic Ewing's sarcoma
por: Golinelli, Giulia, et al.
Publicado: (2021)

GD2 CAR T cells against human glioblastoma
por: Prapa, Malvina, et al.
Publicado: (2021)

Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2023)

Immune characterization of breast cancer metastases: prognostic implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2018)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
por: Golinelli, Giulia, et al.
Publicado: (2018)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

Human Mesenchymal Stem Cell Combined with a New Strontium-Enriched Bioactive Glass: An ex-vivo Model for Bone Regeneration
por: Bellucci, Devis, et al.
Publicado: (2019)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
por: Rossignoli, Filippo, et al.
Publicado: (2019)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
por: Conte, PierFranco, et al.
Publicado: (2023)

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2019)

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2021)

A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
por: Candini, Olivia, et al.
Publicado: (2019)

Author Correction: A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology
por: Candini, Olivia, et al.
Publicado: (2020)

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
por: Miglietta, Federica, et al.
Publicado: (2019)

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
por: Dieci, M V, et al.
Publicado: (2019)

Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review
por: Vernaci, Grazia Maria, et al.
Publicado: (2021)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
por: Massa, Davide, et al.
Publicado: (2022)

Autologous Marrow Mesenchymal Stem Cell Driving Bone Regeneration in a Rabbit Model of Femoral Head Osteonecrosis
por: Mastrolia, Ilenia, et al.
Publicado: (2022)

An overview of immune checkpoint inhibitors in breast cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) Pseudomonas aeruginosa: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
por: Meschiari, Marianna, et al.
Publicado: (2021)

Dendritic cells in reflectance confocal microscopy are a clue for early melanoma diagnosis in extrafacial flat pigmented melanocytic lesions
por: Guiducci, Laura, et al.
Publicado: (2022)

A retrospective cohort study about hip luxation in non-ambulatory cerebral palsy patients: The point of no return
por: Faccioli, Silvia, et al.
Publicado: (2022)

Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Miglietta, Federica, et al.
Publicado: (2021)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
por: Cerma, Krisida, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4341l8jo074hqhs8rrlb6p7kj2